Search Result

Results for "

chronic hepatitis C virus

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HBV (2) HCV (10) Apoptosis (1) Autophagy (1) Bcl-2 Family (1) CDK (1) Claudin (1) Cyclin G-associated Kinase (GAK) (1) Endogenous Metabolite (1) ERK (1) Ferroptosis (1) Glutathione S-transferase (1) HCV Protease (5) HIV (1) HSP (1) IFNAR (1) Interleukin Related (1) JNK (1) Macrophage migration inhibitory factor (MIF) (1) Microtubule/Tubulin (1) MMP (1) mTOR (1) NF-κB (1) P-glycoprotein (1) p38 MAPK (1) Reactive Oxygen Species (ROS) (1) TNF Receptor (1) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (2) Infection (19) Inflammation/Immunology (4)
Oligonucleotides:	CpG ODNs (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Targets Recommended: Hepatitis E Virus (HEV) HCV HBV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0766

Bicyclol SY801	Autophagy Apoptosis HBV HCV HSP Reactive Oxygen Species (ROS) Bcl-2 Family Glutathione S-transferase p38 MAPK NF-κB Microtubule/Tubulin ERK JNK TNF Receptor Interleukin Related CDK Cyclin G-associated Kinase (GAK) mTOR P-glycoprotein Ferroptosis	Infection Inflammation/Immunology Cancer
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .

HY-N0249

Saikosaponin C 2 Publications Verification	MMP	Infection Inflammation/Immunology
Saikosaponin C is an orally active MMP-2 inducer. Saikosaponin C induces the survival, growth, migration and capillary tube formation of endothelial cells. Saikosaponin C inhibits the early stage of hepatitis C virus infection. Saikosaponin C can be used in research related to ischemic tissue diseases, chronic kidney diseases and hepatitis C virus infection .

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-108842

Peginterferon alfa-2b PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg	HIV HCV	Infection Cancer
Peginterferon alfa-2b (PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg) is an immunomodulator. Peginterferon alfa-2b is a recombinant alfa-2b interferon covalently linked PEG with antiviral activity against HCV. Peginterferon alfa-2b decreases viral DNA in HIV. Peginterferon alfa-2b can be used in research of melanoma and hepatitis C .

HY-P991200

OM-7D3-B3	HCV Claudin	Infection
OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (K_d=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .

HY-13337

BMS-986094 INX-08189	HCV	Infection
BMS-986094 (INX-08189) is a potent inhibitor of hepatitis C virus (HCV) replication, with an EC₅₀ of 35 nM at 24 h in Huh-7 cells. BMS-986094 is a phosphoramidate proagent of 6-O-methyl-2’-C-methyl guanosine. BMS-986094 can be used for the research of chronic HCV infection .

HY-117411A

Coblopasvir dihydrochloride KW-136 dihydrochloride	HCV HCV Protease	Infection
Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection .

HY-15256

Faldaprevir BI 201335	HCV Protease	Infection
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .

HY-103487

Uprifosbuvir IDX21437; MK-3682	HCV	Infection
Uprifosbuvir is an antiviral agent. Uprifosbuvir is a NS5b inhibitor developed for the research of chronic hepatitis C virus .

HY-149308

MKA031	Macrophage migration inhibitory factor (MIF)	Infection
MKA031 (compound 6y) is a non-competitive MIF inhibitor with an IC₅₀ value of 1.7 μM. MKA031 (compound 6y) interferes with MIF/AIF interaction, MIF nuclear translocation, and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced dependent cell death. MKA031 can be used in the study of chronic hepatitis C virus infection .

HY-117411

Coblopasvir KW-136	HCV HCV Protease	Infection Inflammation/Immunology
Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection .

HY-14404

MK-1220	HBV HCV Protease	Infection
MK-1220 is a covalently reversible inhibitor of the hepatitis C virus (HCV) NS3/4A protease (NS3/4A protease) with a K_i of 0.02 nM. MK-1220 in cell models simulating viral replication exhibits EC₅₀s of 4 (with 10% fetal bovine serum) and 11 nM (50% normal human serum). MK-1220 can be used for the study of chronic hepatitis C virus infection .

HY-147358C

(1R,4S)-Yimitasvir diphosphate (1R,4S)-Emitasvir diphosphate; (1R,4S)-DAG-181 diphosphate	HCV	Infection
Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection .

HY-13465A

VCH-916 free base	HCV	Infection
VCH-916 free base is the free base form of VCH-916 (HY-13465). VCH-916 free base is an inhibitor for non-nucleoside type NS5B HCV polymerase .

HY-13655A

Isatoribine	Toll-like Receptor (TLR)	Infection
Isatoribine is a TLR7 agonist. Isatoribine is used in the study of chronic hepatitis C virus (HCV) infection .

HY-I0516

PSI 352707 GS-566500	Endogenous Metabolite	Infection
PSI 352707 (GS-566500) is a sofosbuvir metabolite with activity similar to other antiviral compounds. PSI 352707 showed good safety and tolerability in inhibiting chronic hepatitis C virus infection .

HY-165069

N-Docosanoyl-D-erythro-sphingosylphosphorylcholine Sphingomyelin (d18:1 C22:0)	Others	Others
N-Docosanoyl-D-erythro-sphingosylphosphorylcholine (Sphingomyelin (d18:1 C22:0)) is a compound that appears in the plasma sphingolipid profile after chronic hepatitis C virus infection. The level of this substance in plasma is associated with hepatic steatosis and may be an independent factor of hepatic steatosis.

HY-15256A

Faldaprevir sodium BI 201335 sodium	HCV Protease	Infection
Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection .

HY-108839

Peginterferon alfa-2a Ro 25-8310/000	IFNAR	Infection
Peginterferon alfa-2a is a PEG-modified interferon (IFN) alpha-2a. Peginterferon alfa-2a can be used for research of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection .

HY-17619

Ravidasvir PPI-668	HCV	Infection
Ravidasvir (PPI-668) is an orally active pan-genotypic NS5A inhibitor and antiviral agent. Ravidasvir exhibits antiviral activity against HCV genotypes 1 to 6, with EC₅₀ values ranging from 0.04 to 1.14 nM. Ravidasvir shows no or extremely low activity against feline infectious peritonitis virus type II. Ravidasvir can be used in research related to hepatitis C virus infection .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library	391 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

391 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Target	Research Area	Image